EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial

Dave Singh iD, Chaim M Brickman iD, Peter Lloyd iD, Ashish Kalra, Subhabrata Biswas iD, Arkadeep Sinha iD, Alex Mulvanny iD, Sumathi Sivapalasingam iD, Oren M Becker iD, Aaron Deykin iD

Clinical Pharmacology & Therapeutics · 2026-03 · 119 (3) · 782-790

DOI: 10.1002/cpt.70156 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 24.12.2025. Verfasst von Dave Singh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medicines Evaluation Unit, Manchester, UK. Hauptthemen laut MEDLINE: Asthma, Receptors, Cytokine, Antibodies, Monoclonal, Humanized, Anti-Asthmatic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Verekitug, a novel, high‐affinity, fully human monoclonal antibody targeting thymic stromal lymphopoietin receptor (TSLPR), is in development as a potential treatment for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD). This phase 1b, double‐blind, randomized, placebo‐controlled, multiple ascending‐dose trial assessed the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of verekitug administered subcutaneously in patients with mild–moderate asthma. Thirty‐two participants were randomized in 4 placebo‐controlled dosing cohorts (3 × 100‐mg or 200‐mg doses, once every 4 weeks; 2 × 300‐mg doses, once every 12 weeks; single 25‐mg dose) and observed for 32 weeks. The primary endpoint was safety; secondary endpoints were pharmacokinetics and immunogenicity. Exploratory endpoints included TSLPR occupancy and biomarker effects. Treatment‐emergent adverse events were mild or moderate. Complete TSLPR occupancy was observed at the first timepoint (2 weeks post dose) and maintained for 24 weeks (doses ≥100 mg). Rapid mean reductions in fractional exhaled nitric oxide, eosinophils, and interleukin‐5 (up to −54%, −65%, and −64%, respectively) were sustained up to 24 weeks (doses ≥100 mg). The mean verekitug half‐life was ~20 days. Low‐titer antidrug antibody response was observed in some participants, without clinically meaningful impact on pharmacokinetics, pharmacodynamics, or safety. Verekitug was generally well tolerated, with rapid, substantial, and sustained effects on asthma biomarkers. These findings support further development of verekitug for treating severe asthma, CRSwNP, and COPD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaReceptors, CytokineAntibodies, Monoclonal, HumanizedAnti-Asthmatic AgentsAntibodies, MonoclonalHumansMaleFemaleMiddle AgedDouble-Blind MethodAdultDose-Response Relationship, DrugAgedTreatment OutcomeYoung Adult

Substanzen

Receptors, CytokineAntibodies, Monoclonal, HumanizedCRLF2 protein, humanAnti-Asthmatic AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Medicines Evaluation Unit, Manchester, UK.
  • University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.
  • Chaim Brickman Consulting Ltd., Zur Hadassah, Israel.
  • KinDyn Consulting Ltd., Warnham, UK.
  • Upstream Bio Inc., Waltham, MA, USA.
  • Oren Becker Consulting Ltd., Mevasseret Zion, Israel.

ORCID-Profile: Dave Singh, Chaim M Brickman, Peter Lloyd, Subhabrata Biswas, Arkadeep Sinha, Alex Mulvanny, Sumathi Sivapalasingam, Oren M Becker, Aaron Deykin

Zitieren

APA

Singh, D., Brickman, C. M., Lloyd, P., Kalra, A., Biswas, S., Sinha, A., Mulvanny, A., Sivapalasingam, S., Becker, O. M., & Deykin, A. (2026). Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial. Clinical Pharmacology & Therapeutics, 119(3), 782-790. https://doi.org/10.1002/cpt.70156

Vancouver

Singh D, Brickman CM, Lloyd P, Kalra A, Biswas S, Sinha A, et al. Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial. Clinical Pharmacology & Therapeutics. 2026;119(3):782-790. doi:10.1002/cpt.70156

BibTeX
@article{Singh2026,
  author = {Singh, Dave and Brickman, Chaim M and Lloyd, Peter and Kalra, Ashish and Biswas, Subhabrata and Sinha, Arkadeep and Mulvanny, Alex and Sivapalasingam, Sumathi and Becker, Oren M and Deykin, Aaron},
  title = {Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {119},
  number = {3},
  pages = {782--790},
  doi = {10.1002/cpt.70156}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche